This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this book Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fazio, S. Articles by Biondi, B. Search for Related Content PubMed PubMed Citation Articles by Fazio, S. Articles by Biondi, B.

Effects of Thyroid Hormone on the Cardiovascular System

Serafino Fazio^*, Emiliano A. Palmieri^*, Gaetano Lombardi and Bernadette Biondi

^* Department of Clinical Medicine and Cardiovascular Sciences, University of Naples "Federico II" School of Medicine, 80131, Naples, Italy
Department of Clinical and Molecular Endocrinology and Oncology, University of Naples "Federico II" School of Medicine, 80131, Naples, Italy

Increased or reduced action of thyroid hormone on certain molecular pathways in the heart and vasculature causes relevant cardiovascular derangements. It is well established that overt hyperthyroidism induces a hyperdynamic cardiovascular state (high cardiac output with low systemic vascular resistance), which is associated with a faster heart rate, enhanced left ventricular (LV) systolic and diastolic function, and increased prevalence of supraventricular tachyarrhythmias — namely, atrial fibrillation — whereas overt hypothyroidism is characterized by the opposite changes. However, whether changes in cardiac performance associated with overt thyroid dysfunction are due mainly to alterations of myocardial contractility or to loading conditions remains unclear. Extensive evidence indicates that the cardiovascular system responds to the minimal but persistent changes in circulating thyroid hormone levels, which are typical of individuals with subclinical thyroid dysfunction. Subclinical hyperthyroidism is associated with increased heart rate, atrial arrhythmias, increased LV mass, impaired ventricular relaxation, reduced exercise performance, and increased risk of cardiovascular mortality. Subclinical hypothyroidism is associated with impaired LV diastolic function and subtle systolic dysfunction and an enhanced risk for atherosclerosis and myocardial infarction. Because all cardiovascular abnormalities are reversed by restoration of euthyroidism ("subclinical hypothyroidism") or blunted by ß-blockade and L-thyroxine (L-T4) dose tailoring ("subclinical hyperthyroidism"), timely treatment is advisable in an attempt to avoid adverse cardiovascular effects. Interestingly, some data indicate that patients with acute and chronic cardiovascular disorders and those undergoing cardiac surgery may have altered peripheral thyroid hormone metabolism that, in turn, may contribute to altered cardiac function. Preliminary clinical investigations suggest that administration of thyroid hormone or its analogue 3,5-diiodothyropropionic acid greatly benefits these patients, highlighting the potential role of thyroid hormone treatment in patients with acute and chronic cardiovascular disease.

This article has been cited by other articles:

				C. F. A. Eustatia-Rutten, E. P. M. Corssmit, K. A. Heemstra, J. W. A. Smit, R. C. Schoemaker, J. A. Romijn, and J. Burggraaf Autonomic Nervous System Function in Chronic Exogenous Subclinical Thyrotoxicosis and the Effect of Restoring Euthyroidism J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2835 - 2841. [Abstract] [Full Text] [PDF]

				B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]

				A. Iqbal, H. Schirmer, P. Lunde, Y. Figenschau, K. Rasmussen, and R. Jorde Thyroid Stimulating Hormone and Left Ventricular Function J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3504 - 3510. [Abstract] [Full Text] [PDF]

				M. D. Gammage, J. V. Parle, R. L. Holder, L. M. Roberts, F. D. R. Hobbs, S. Wilson, M. C. Sheppard, and J. A. Franklyn Association Between Serum Free Thyroxine Concentration and Atrial Fibrillation Arch Intern Med, May 14, 2007; 167(9): 928 - 934. [Abstract] [Full Text] [PDF]

				A.-L. Fabrizio, D. B. Vitantonio, T. Enrica, D. C. Andrea, M. Fabio, A. Lucia, P. Caterina, C. Nadia, D. D. M. Grazia, N. Carmela, et al. Early textural and functional alterations of left ventricular myocardium in mild hypothyroidism. Eur. J. Endocrinol., July 1, 2006; 155(1): 3 - 9. [Abstract] [Full Text] [PDF]

				T. Nagasaki, M. Inaba, Y. Kumeda, Y. Hiura, K. Shirakawa, S. Yamada, Y. Henmi, E. Ishimura, and Y. Nishizawa Increased Pulse Wave Velocity in Subclinical Hypothyroidism J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 154 - 158. [Abstract] [Full Text] [PDF]

				J. W. A. Smit, C. F. A. Eustatia-Rutten, E. P. M. Corssmit, A. M. Pereira, M. Frolich, G. B. Bleeker, E. R. Holman, E. E. van der Wall, J. A. Romijn, and J. J. Bax Reversible Diastolic Dysfunction after Long-Term Exogenous Subclinical Hyperthyroidism: A Randomized, Placebo-Controlled Study J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6041 - 6047. [Abstract] [Full Text] [PDF]

				G. J. Kahaly and W. H. Dillmann Thyroid Hormone Action in the Heart Endocr. Rev., August 1, 2005; 26(5): 704 - 728. [Abstract] [Full Text] [PDF]

				L. Johansson, M. Rudling, T. S. Scanlan, T. Lundasen, P. Webb, J. Baxter, B. Angelin, and P. Parini Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice PNAS, July 19, 2005; 102(29): 10297 - 10302. [Abstract] [Full Text] [PDF]

				F. Santini, A. Pinchera, A. Marsili, G. Ceccarini, M. G. Castagna, R. Valeriano, M. Giannetti, D. Taddei, R. Centoni, G. Scartabelli, et al. Lean Body Mass Is a Major Determinant of Levothyroxine Dosage in the Treatment of Thyroid Diseases J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 124 - 127. [Abstract] [Full Text] [PDF]